Zobrazeno 1 - 10
of 242
pro vyhledávání: '"J. Lenting"'
Autor:
Michael E. Cloesmeijer, Erik Sjögren, Sjoerd F. Koopman, Peter. J. Lenting, Marjon H. Cnossen, Ron A. A. Mathôt, the OPTI‐CLOT study group and SYMPHONY consortium
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 13, Iss 10, Pp 1630-1640 (2024)
Abstract Patients with severe and sometimes moderate hemophilia B are prophylactically treated with factor IX concentrates to prevent bleeding. For some time now, various extended terminal half‐life (EHL) recombinant factor IX concentrates are avai
Externí odkaz:
https://doaj.org/article/5f163a5353a04a9587192c9f9d3e1653
Autor:
Jan Blatný, Jan Astermark, Cristina Catarino, Gerry Dolan, Karin Fijnvandraat, Cédric Hermans, Katharina Holstein, Víctor Jiménez-Yuste, Robert Klamroth, Michelle Lavin, Peter J. Lenting, Sébastien Lobet, Maria Elisa Mancuso, Jayashree Motwani, James S. O’Donnell, Christoph Königs
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Over recent decades, management of people with hemophilia (PwH) has been greatly improved by scientific advances that have resulted in a rich and varied therapeutic landscape. Nevertheless, treatment limitations continue to drive innovation, and emer
Externí odkaz:
https://doaj.org/article/49b84b74635547b39a4cb8316ffbb30c
Autor:
Thibaud Sefiane, Hortense Maynadié, Carmen Escurola Ettingshausen, Vincent Muczynski, Xavier Heiligenstein, Julien Dumont, Olivier D. Christophe, Cécile V. Denis, Caterina Casari, Peter J. Lenting
Publikováno v:
Haematologica, Vol 109, Iss 6 (2023)
Recombinant factor VIII (rFVIII), rFVIIIFc and emicizumab are established treatment options in the management of hemophilia A. Each has its unique mode of action, which can influence thrombin generation kinetics and therefore also the kinetics of thr
Externí odkaz:
https://doaj.org/article/87dfb0cfe60b4523b7deb3413f713473
Autor:
Marie‐Daniéla Dubois, Ivan Peyron, Olivier‐Nicolas Pierre‐Louis, Serge Pierre‐Louis, Johalène Rabout, Pierre Boisseau, Annika deJong, Sophie Susen, Jenny Goudemand, Rémi Neviere, Pascal Fuseau, Olivier D. Christophe, Peter J. Lenting, Cécile V. Denis, Caterina Casari
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 6, Iss 4, Pp n/a-n/a (2022)
Abstract Background Von Willebrand disease was diagnosed in two Afro‐Caribbean patients and sequencing of the VWF gene (VWF) revealed the presence of multiple variants located throughout the gene, including variants located in the D4 domain of VWF:
Externí odkaz:
https://doaj.org/article/b5a5473594134f32afc891cac997479f
Autor:
Ivan Peyron, Claire Kizlik‐Masson, Marie‐Daniéla Dubois, Sénadé Atsou, Stephen Ferrière, Cécile V. Denis, Peter J. Lenting, Caterina Casari, Olivier D. Christophe
Publikováno v:
Research and Practice in Thrombosis and Haemostasis, Vol 4, Iss 7, Pp 1087-1110 (2020)
Abstract Hemostasis is a complex process involving the concerted action of molecular and vascular components. Its basic understanding as well as diagnostic and therapeutic aspects have greatly benefited from the use of monoclonal antibodies. Interest
Externí odkaz:
https://doaj.org/article/28833a87b34b49a9b8815afa9a9a3cb5
Autor:
Giulia Pavani, Marine Laurent, Anna Fabiano, Erika Cantelli, Aboud Sakkal, Guillaume Corre, Peter J. Lenting, Jean-Paul Concordet, Magali Toueille, Annarita Miccio, Mario Amendola
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-13 (2020)
A platform for systemic therapeutic transgene expression independent of patient mutations needs a safe and highly transcribed locus. Here the authors ex vivo edit HPSCs using CRISPR-Cas9 to integrate transgenes under the α-globin promoter to achieve
Externí odkaz:
https://doaj.org/article/bd6f18164a234100805135163a84adaa
Autor:
Elena Barbon, Gabriel Ayme, Amel Mohamadi, Jean‐François Ottavi, Charlotte Kawecki, Caterina Casari, Sebastien Verhenne, Solenne Marmier, Laetitia van Wittenberghe, Severine Charles, Fanny Collaud, Cecile V Denis, Olivier D Christophe, Federico Mingozzi, Peter J Lenting
Publikováno v:
EMBO Molecular Medicine, Vol 12, Iss 4, Pp 1-18 (2020)
Abstract Novel therapies for hemophilia, including non‐factor replacement and in vivo gene therapy, are showing promising results in the clinic, including for patients having a history of inhibitor development. Here, we propose a novel therapeutic
Externí odkaz:
https://doaj.org/article/4434607219fc41c0b6465b55049e9dff
Autor:
Caterina Casari, Remi Favier, Paulette Legendre, Alexandre Kauskot, Frederic Adam, Veronique Picard, Peter J. Lenting, Cecile V. Denis, Valerie Proulle
Publikováno v:
Therapeutic Advances in Hematology, Vol 13 (2022)
This report describes the first case of splenic injury in a patient with p.V1316M-associated von Willebrand disease type 2B (VWD2B) with chronic thrombocytopenia, successfully treated with nonoperative management including von Willebrand factor (VWF)
Externí odkaz:
https://doaj.org/article/f46a35a8466e49af9e0fca1439be9097
Autor:
Cécile V. Denis, Peter J. Lenting
Publikováno v:
Haematologica, Vol 107, Iss 9 (2021)
Externí odkaz:
https://doaj.org/article/9b08e5499b5949308589dae04fe1485a
Publikováno v:
Journal of Thrombosis and Haemostasis. 21:710-713
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be447c9be572982243dfc84e1bf1ebbb
https://doi.org/10.1016/j.jtha.2023.01.014
https://doi.org/10.1016/j.jtha.2023.01.014